Cross-institution positioning
Jan 30, 2026Reduction leaning. 1 accumulating, 1 exited across 2 comparable institutions.
Source: Schedule 13 researchAVITA Medical, Inc.
Latest stored close $13.21 as of Oct 9, 2026 View live quote ↗
See how each tracked institution's reported ownership changed across SEC position dates. Full history is available with Investor or Pro access.
What the evidence shows across the newest institutional, insider, company-event, 13F, fundamental, and price data; STOCKNODE combines these layers into a quantitative research signal while preserving each source and reporting window.
Reduction leaning. 1 accumulating, 1 exited across 2 comparable institutions.
Source: Schedule 13 research0 increased/new, 2 reduced/exited across 2 managers in the latest comparable Form 13F quarter.
Source: Form 13F quarter-end holdingsOver the last 90 days, SEC-coded non-derivative P/S activity includes 9 purchases by 1 reporting owner and 0 sales by 0 reporting owners. Amendments are shown in the filing evidence but excluded from rolling activity totals.
Source: SEC Forms 3/4/53 non-amendment material events in the last 90 days; 1 capital-related filing/event (1 equity-related, 0 debt-related); Latest classified evidence: Employee-plan securities registration. Registration and prospectus filings are treated as financing capacity/disclosure evidence, not proof that securities were sold.
Source: SEC 8-K / securities filing metadataRevenue +17.8% YoY; Net income +22.8% YoY. Periods are compared only when the SEC facts are aligned and comparable.
Source: SEC Company FactsRecent close is 86% through its reported 52-week range; +51.0% over one year.
Source: Stored historical price seriesFiled Jan 30, 2026. Unlock the dated position comparison, disclosure classification, confidence, price context, and filing-specific significance analysis.
Premium research values are withheld until unlocked.
The research summary above gives the current read. This section shows the dated holder-level evidence behind it.
See each institution's newest reported position against its own prior report, with position as-of date separated from SEC filed date. Institution names and filing freshness remain public below.
Comparable holder direction grouped by SEC position as-of date — never presented as trade dates.
Compare each institution only with its own prior reported position. Public visitors can see who is tracked and how fresh the filing is; paid research reveals the actual comparison.
Investor and Pro reveal holder-by-holder changes, reported ownership history, dated breadth, disclosure timing, institution comparison, and filing-specific analysis without treating Schedule 13 reports as trade dates.
Reported Section 16 ownership activity. Rolling purchase/sale totals use non-derivative SEC transaction codes P and S only; amendments remain visible but are excluded from those totals.
| Date | Reporting owner | Code | Security | Shares | Price | Ownership | Filed |
|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | O'Toole David D | POpen-market or private purchase · amendment | Common Stock | 2.0K | $3.97 | Direct | Aug 24, 2026 |
| Jun 12, 2026 | O'Toole David D | AGrant, award, or other acquisition | Common Stock | 2.0K | $3.97 | Direct | Jun 12, 2026 |
| Jun 9, 2026 | Woody Joseph Fralin | POpen-market or private purchase | Common Stock | 5.2K | $4.00 | Direct | Jun 10, 2026 |
| Jun 9, 2026 | Woody Joseph Fralin | POpen-market or private purchase | Common Stock | 5.0K | $4.18 | Direct | Jun 9, 2026 |
| Jun 9, 2026 | Woody Joseph Fralin | POpen-market or private purchase | Common Stock | 5.0K | $4.20 | Direct | Jun 9, 2026 |
| Jun 3, 2026 | Woody Joseph Fralin | POpen-market or private purchase | Common Stock | 5.0K | $4.09 | Direct | Jun 5, 2026 |
| Jun 3, 2026 | Woody Joseph Fralin | POpen-market or private purchase | Common Stock | 5.0K | $4.10 | Direct | Jun 5, 2026 |
| Jun 2, 2026 | Woody Joseph Fralin | POpen-market or private purchase | Common Stock | 5.0K | $4.21 | Direct | Jun 3, 2026 |
| Jun 2, 2026 | Woody Joseph Fralin | POpen-market or private purchase | Common Stock | 5.0K | $4.18 | Direct | Jun 3, 2026 |
| Jun 1, 2026 | Woody Joseph Fralin | POpen-market or private purchase | Common Stock | 5.0K | $4.26 | Direct | Jun 3, 2026 |
| Jun 1, 2026 | Woody Joseph Fralin | POpen-market or private purchase | Common Stock | 5.0K | $4.34 | Direct | Jun 3, 2026 |
| May 29, 2026 | O'Toole David D | AGrant, award, or other acquisition | Common Stock | 5.0K | $3.05 | Direct | Jun 1, 2026 |
| May 29, 2026 | Vance Cary Guy | AGrant, award, or other acquisition | Common Stock | 5.0K | $3.05 | Direct | Jun 1, 2026 |
| May 20, 2026 | O'Toole David D | POpen-market or private purchase | Common Stock | 2.0K | $4.26 | Direct | May 20, 2026 |
| May 19, 2026 | O'Toole David D | POpen-market or private purchase | Common Stock | 2.0K | $4.24 | Direct | May 19, 2026 |
| Jan 20, 2026 | McNamara Robert | AGrant, award, or other acquisition · derivative | Stock Options (Right to Buy) | 16.1K | $0.00 | Direct | Jun 4, 2026 |
| Jan 20, 2026 | McNamara Robert | AGrant, award, or other acquisition | Common Stock | 22.2K | — | Direct | Jun 4, 2026 |
| Jan 20, 2026 | Woody Joseph Fralin | AGrant, award, or other acquisition · derivative | Stock Options (Right to Buy) | 16.1K | $0.00 | Direct | Jun 4, 2026 |
| Jan 20, 2026 | Woody Joseph Fralin | AGrant, award, or other acquisition | Common Stock | 22.2K | — | Direct | Jun 4, 2026 |
| Jan 20, 2026 | Tarnoff Michael E | AGrant, award, or other acquisition · derivative | Stock Options (Right to Buy) | 16.1K | $0.00 | Direct | Jun 4, 2026 |
Recent 8-K item classifications plus securities registration and prospectus filings. Registration or prospectus filings show financing capacity/disclosure activity; they do not by themselves prove that securities were sold.
| Filed | Form | 8-K item(s) | Classification | Capital context | SEC |
|---|---|---|---|---|---|
| Aug 25, 2026 | S-8 | — | Employee-plan securities registration | Equity | Filing |
| Aug 11, 2026 | 8-K | 1.01, 9.01 | Material definitive agreement; Financial statements / exhibits | — | Filing |
| Aug 6, 2026 | 8-K/AAmendment | 5.07 | Shareholder vote results | — | Filing |
| Aug 6, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Jun 8, 2026 | 8-K | 1.01, 9.01 | Material definitive agreement; Financial statements / exhibits | — | Filing |
| Jun 8, 2026 | 424B5 | — | Prospectus filing | Capital-related | Filing |
| Jun 4, 2026 | 8-K | 5.02, 5.07 | Director or executive change; Shareholder vote results | — | Filing |
| May 14, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| May 1, 2026 | 8-K | 5.02, 7.01, 9.01 | Director or executive change; Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Mar 31, 2026 | S-3 | — | Shelf securities registration | Capital-related | Filing |
| Feb 12, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Jan 13, 2026 | 8-K | 1.01, 1.02, 2.02, 2.03, 3.02, 9.01 | Material definitive agreement; Termination of material agreement; Results of operations / financial condition; New direct financial obligation; Unregistered sale of equity securities; Financial statements / exhibits | Equity | Filing |
Period-aligned SEC facts. Comparisons appear only when periods and units are comparable.
| Period | Revenue | YoY |
|---|---|---|
| Ended Jun 30, 2026 | $21.7M | +17.8% |
| Ended Mar 31, 2026 | $19.3M | +4.0% |
| Ended Sep 30, 2025 | $17.1M | -12.7% |
| Ended Jun 30, 2025 | $18.4M | +21.2% |
| Period | Revenue | YoY |
|---|---|---|
| Ended Dec 31, 2025 | $71.6M | +11.5% |
| Ended Dec 31, 2024 | $64.3M | +28.1% |
| Ended Dec 31, 2023 | $50.1M | +45.7% |
| Ended Dec 31, 2022 | $34.4M | — |
Dated price context from the historical market series already collected for this security.
Returns are close-to-close price changes. Volatility and drawdown are factual historical context, not recommendations.
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| Vanguard Group CIK0000102909 | Dec 31, 2025 observed Jan 30, 2026 filed · 30d Schedule 13G amendment | Exit below reporting threshold | 1.4M +51.8K | 4.73% -0.72 pts | $3.45 | $4.41 | $13.21 |
| BlackRock CIK0002012383 | Sep 30, 2025 observed Oct 17, 2025 filed · 17d Schedule 13G amendment | Earliest Schedule 13G amendment found | 1.1M | 12.00% | $5.11 | $3.99 | $13.21 |
| BlackRock CIK0002012383 | Sep 30, 2024 quarter end Nov 13, 2024 filed Form 13F quarter-end evidence | Earlier Form 13F quarter-end holding Quarter-end holding evidence; no ownership percentage or signal. | 1.9M | $10.72 | $12.87 | $13.21 |
Compare RCEL with other securities showing similar institutional activity or recent accumulation across several tracked institutions.